Abbott India's (BOOT) Q2FY19 sales were below our expectations by 6% while PAT was a miss by 4.2% against our expectations. Total revenues were up by 5.2% YoY (16% QoQ) at Rs9.8bn driven by higher volumes. EBITDA margins were at 19.8% (est. of 18.5%) up from 13.2% in Q1FY19 given lower staff costs and other expenses. APAT was flat YoY while 4.2% below our estimates at Rs1,377mn (est. Rs1,437mn). Regulatory hurdles have been continuously impacting the revenues of the company. However, we expect growth in-line with the industry on the back of volume growth in its flagship brands and patent product launches from parent....